topic

93 Targeting sirt2 rescues the metabolic fitness and effector functions of tumor-reactive T cells within the metabolically restricted tumor microenvironment
Imene Hamaidi, Lin Zhang, Nayoung Kim, Min-Hsuan Wang, Cristina Iclozan, Bin Fang, Min Liu, John Koomen, Anders Berglund, Sean Yoder, Jiqiang Yao, Robert Engelman, Ben Creelan, Jose Conejo-Garcia, Scott Antonia, James Mule, Sungjune Kim

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A59; DOI: 10.1136/jitc-2020-SITC2020.0093
94 The T cell antigen coupler (TAC) redirects T cell oncolysis while limiting tonic signaling to create a safer engineered T cell product with a higher threshold for activation
Duane Moogk, Vivian Lau, Arya Afsahi, Anna Dvorkin-Gheva, Ksenia Bezverbnaya, Joanne Hammill, Jonathan Bramson

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A59-A60; DOI: 10.1136/jitc-2020-SITC2020.0094
10 A multiparameter flow cytometry assay to monitor natural killer cell proliferation and activation in immuno-oncology clinical trials
Jennifer Tsau, Brittney Atzmiller, David Quinn, Tanya Mulvey, Sema Kurtulus, Jennifer Mataraza, Shabnam Tangri, Naveen Dakappagari, Ghanashyam Sarikonda

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A6; DOI: 10.1136/jitc-2020-SITC2020.0010
11 A multi-physics approach enabling rare cell isolation with high recovery and high purity
Liping Yu, Silin Sa, Alice Wang

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A6-A7; DOI: 10.1136/jitc-2020-SITC2020.0011
100 Drug-regulatable engineered T cells eliminate CD33+ and CD33ΔE2+ AML
Jacob Appelbaum, Wai-Hang Leung, Unja Martin, Kaori Oda, Giacomo Tampella, Dong Xia, Joy Zhang, Anne-Rachael Krostag, Rachael Logan, Claudya Evandy, Quennie Vong, Kyle Jones, John Timmer, Brendan Eckelman, Jim Rottman, Danielle Montt, Bryan Peguero, Mark Pogson, Alexander Astrakhan, Jordan Jarjour, Joshua Gustafson, Michael Jensen

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A63; DOI: 10.1136/jitc-2020-SITC2020.0100
101 Engineering gamma/delta T cells with the T-Cell antigen coupler receptor effectively induces antigen-specific tumor cytotoxicity in vitro and in vivo
Sarah Asbury, Seung Mi Yoo, Jonathan Bramson

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A63-A64; DOI: 10.1136/jitc-2020-SITC2020.0101
103 Inclusion of a Dap10 costimulatory domain enhances anti-tumor efficacy of chimeric PD1-expressing T cells in multiple types of solid tumors
Amorette Barber

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A64-A65; DOI: 10.1136/jitc-2020-SITC2020.0103
106 Increasing AMPK activity in human T cells enhances memory subset formation without sacrificing in vitro expansion
Erica Braverman, Andrea Dobbs, Darlene Monlish, Craig Byersdorfer

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A66-A67; DOI: 10.1136/jitc-2020-SITC2020.0106
107 Effects of IL-2 and IL-15 on the proliferative and antitumor capacities of allogeneic CD20 CAR-engineered γδ T cells in a 3D B cell lymphoma spheroid assay
Lu Bai, Kevin Nishimoto, Mustafa Turkoz, Marissa Herrman, Jason Romero, Daulet Satpayev, Stewart Abbot, Sandra Hayes, Mary Brodey

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A67; DOI: 10.1136/jitc-2020-SITC2020.0107
108 MCY-M11, a CAR-PBMC cell product transiently expressing a mesothelin targeted mRNA CAR, exhibits desirable functional and immune phenotype attributed to sustained antitumor immunity in vitro
Sashi Kasimsetty, Himavanth Gatla, Dhana Chinnasamy

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A67-A68; DOI: 10.1136/jitc-2020-SITC2020.0108

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages